Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galectin Therapeutics Inc.

http://www.galectintherapeutics.com

Latest From Galectin Therapeutics Inc.

Bioeq’s Lucentis Biosimilar Is Given EU Go-Ahead

Bioeq’s Ranivisio ranibizumab biosimilar has gained European Commission authorization for all innovator indications including wet AMD, the leading cause of blindness among over-65s.

Biosimilars Approvals

Formycon Reports Positive Phase III Data On Ustekinumab

Formycon has reported positive preliminary efficacy and safety data from the Phase III program for its FYB202 proposed ustekinumab biosimilar rival to Stelara.

Biosimilars Clinical Trials

Cimerli Interchangeable Biosimilar Approved Without Switching Data

Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.

Approvals Biosimilars

Interchangeable Biosimilar Approved Without Switching Data; Cimerli To Compete With Lucentis

Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.

Approvals Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Other Names / Subsidiaries
    • Galectin Sciences, LLC
    • Pro-Pharmaceuticals Inc.
    • Galectin Therapeutics Security Corp.
UsernamePublicRestriction

Register